# Takeda Pharmaceutical

Type: Company (TAK)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/takeda-pharmaceutical
Canonical HTML page: https://getfinancebrief.com/entity/takeda-pharmaceutical

## Recent coverage (1 stories)

### Protagonist Authorizes $300M Buyback With $849M Cash Pile
2026-09-08 22:28:09 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Protagonist Therapeutics has authorized up to $300 million in buybacks, funded by an $849.5 million cash position and upcoming Takeda collaboration payments. Investors will watch how aggressively management repurchases shares and whether the program signals undervaluation or a lack of higher-return investments.
Full story: https://getfinancebrief.com/story/protagonist-300m-buyback-capital-return-play

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.